デフォルト表紙
市場調査レポート
商品コード
1750632

鎌状赤血球貧血症の迅速POC検査の世界市場規模、シェア、動向分析レポート:タイプ別、技術別、用途別、機関タイプ別、最終用途別、流通チャネル別、地域別、セグメント別予測(2025年~2030年)

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Size, Share & Trends Analysis Report By Type, By Technology, By Age Group, By Distribution Channel, By End Use, By Region, And Segment Forecasts, 2025 - 2030


出版日
ページ情報
英文 320 Pages
納期
2~10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.42円
鎌状赤血球貧血症の迅速POC検査の世界市場規模、シェア、動向分析レポート:タイプ別、技術別、用途別、機関タイプ別、最終用途別、流通チャネル別、地域別、セグメント別予測(2025年~2030年)
出版日: 2025年05月02日
発行: Grand View Research
ページ情報: 英文 320 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

鎌状赤血球貧血症の迅速POC検査市場の成長と動向:

Grand View Research, Inc.の最新レポートによると、世界の鎌状赤血球貧血症の迅速POC検査の市場規模は、2025年~2030年にCAGR9.7%を記録し、2030年までに5億2,283万米ドルに達する見込みです。

鎌状赤血球症(SCD)は、異常な形状の赤血球が産生される遺伝的な血液疾患であり、激しい痛み、貧血、血流を阻害する鎌状赤血球による臓器障害の可能性があります。Journal of Hematology and Allied Science(JHAS)によると、インドは鎌状Bグロビン対立遺伝子の頻度が最も高い国の1つです。SCDを早期かつ正確に発見することは、効果的な管理・治療を行う上で非常に重要です。従来の診断法では、専門的なヘルスケア施設や設備の整った検査室が必要とされることが多く、資源が限られている地域ではアクセスできないことがあります。このような課題から、より効率的で利用しやすいSCDの診断法として、迅速POC(ポイント・オブ・ケア)検査が注目されています。

POC検査には、迅速な結果、使いやすさ、分散化したヘルスケア環境への適合性など、いくつかの利点があります。これらの特長は、早期診断と早期介入が患者の予後を大幅に改善するSCD有病率の高い地域では特に有利です。POC検査はタイムリーな発見を可能にすることで、未診断のSCDに関連する重篤な合併症や死亡のリスクを低減し、より良い疾患管理に役立ちます。さらに、POC検査は新生児スクリーニングプログラムにおいて重要な役割を果たし、出生時に罹患児を特定し、直ちに治療を開始するのに役立ちます。最近のラテラルフロー免疫測定法(LFIA)の進歩は、特に低資源環境におけるSCDの診断を大幅に改善しました。革新的な開発の1つが、多重化された対立遺伝子特異的リコンビナーゼポリメラーゼ増幅(RPA)アッセイです。さらに、LFIAプラットフォームに光学ナノ粒子を組み込むことで、これらの検査の感度と特異性が向上し、SCDやその他の疾患の強力な診断ツールとなりました。

もう1つの注目すべき技術革新は、中低所得国(LMIC)における大規模なSCDスクリーニング用に設計されたE-junctionラテラルフロー免疫測定法です。この安価で使いやすいPOC装置は、たった1滴の全血で健常人、SCD患者、保因者を診断することができます。その費用対効果と信頼性から、従来の診断方法へのアクセスが限られている地域に最適であり、診断の遅れによって引き起こされる高い死亡率に対処するのに役立ちます。同様に、Sickle SCAN POC装置は、ヘモグロビン変異体HbA、HbS、HbCの検出において、優れた感度と特異性を示します。この検査は、胎児ヘモグロビン(HbF)を多く含む検体でも、液体血液と乾燥血液スポット(DBS)の両方で効果的に機能するため、資源に制約のある地域での広範なスクリーニングに最適です。SCD早期発見のもう1つの有望な手段であるHemoTypeSC検査も高感度かつ特異的であり、特に大規模なスクリーニングプログラムに有用です。多くの場合NGOが主導する移動医療ユニットやコミュニティへのアウトリーチ・プログラムもまた、資源の乏しい環境において迅速POC検査を提供するために不可欠です。このような努力は、診断サービスへのアクセスを向上させるだけでなく、SCDと早期介入の重要性についての認識を高めます。さらに、NGOと非公開会社間のパートナーシップは、診断検査への助成を助け、様々なヘルスケア環境において、より安価で拡張可能なものとなっています。

国家鎌状赤血球貧血症撲滅ミッション(NSCAEM)のような的を絞ったイニシアチブは、普遍的なスクリーニング、意識向上キャンペーン、疾病管理の改善を通じて、2047年までに公衆衛生問題としての鎌状赤血球貧血症を撲滅することを目指しています。このミッションでは、まずグジャラート州やマハラシュトラ州のような有病率の高い州を中心に、0~40歳の約7,000万人にスクリーニングを実施することを目標としており、その一方で、資源の有効活用のために国民保健ミッション(NHM)と協力しています。

鎌状赤血球貧血症の迅速POC検査市場レポートのハイライト

  • タイプ別では、ラテラルフローイムノアッセイセグメントが、その手頃な価格、使いやすさ、迅速で正確な結果により、2024年に51.66%のシェアで市場をリードしました。LFIAは複数のヘモグロビン変異体を検出でき、低資源環境にも適しているため、世界の診断薬市場で採用が進んでいます。
  • 技術別では、ヘモグロビン電気泳動法がヘモグロビン異常症の検出精度の高さに牽引され、2024年には48.99%のシェアで市場をリードしました。信頼性の高い診断法として、鎌状赤血球症やその他のヘモグロビン変異体の正確な同定が可能であり、早期介入や疾患管理に不可欠です。
  • 用途別では、新生児スクリーニング(12カ月以下)セグメントが2024年の市場をリードしており、認知度の高まりと早期診断の重要性により、予測期間中最も速いCAGRが見込まれます。POC検査による早期発見は、迅速な治療を可能にし、合併症を減らし、罹患した乳児の長期転帰を改善します。
  • 政府ラボセグメントは、国家的イニシアティブと技術の進歩に牽引され、著しい成長を遂げています。インド医学研究評議会(ICMR)は、鎌状赤血球症スクリーニングのための既存のPOC検査を承認し、各州にレベル1またはレベル2のスクリーニングアプローチを実施するよう奨励しています。
  • 病院・診療所の最終用途セグメントは、鎌状赤血球症の有病率の増加とタイムリーな診断への需要に牽引され、大幅な成長を遂げています。
  • 流通チャネル別では、B2B(企業間取引)セグメントが、アクセスしやすく効率的な診断ソリューションに対する需要の増加により、大きな成長を遂げています。各社は戦略的パートナーシップを結び、提供する製品を拡大し、より幅広い市場に参入しています。
  • 鎌状赤血球貧血症のための迅速POC検査業界は、アクセスしやすく効率的な診断ソリューションへの需要増に牽引され、北米が2024年に43.97%の売上シェアで世界を席巻しました。この拡大は、慢性疾患の有病率の上昇、診断技術の進歩、政府や民間機関からの資金提供の増加などの要因によるものです。
  • BioMedomicsやSilver Lake Researchのような主要企業は、それぞれSickle SCANやHemoTypeSCのような高感度かつ特異的な検査で市場をリードしています。これらの企業が診断能力を高め、納期を短縮し、鎌状赤血球症の早期介入を支援することで、市場は成長に向かっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 鎌状赤血球貧血症の迅速POC検査市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 鎌状赤血球貧血症の迅速POC検査市場の分析ツール
    • 業界分析:ポーターのファイブフォース分析
    • PESTEL分析

第4章 鎌状赤血球貧血症の迅速POC検査市場:タイプの推定・動向分析

  • タイプの市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:タイプ別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • ラテラルフローイムノアッセイ
    • 紙ベースの迅速診断
    • その他

第5章 鎌状赤血球貧血症の迅速POC検査市場:技術の推定・動向分析

  • 技術の市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:技術別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • ヘモグロビン電気泳動法
    • ポリメラーゼ連鎖反応(PCR)
    • 等温増幅アッセイ
    • その他

第6章 鎌状赤血球貧血症の迅速POC検査市場:用途の推定・動向分析

  • 用途の市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:用途別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • 新生児スクリーニング(12か月以下)
    • 成人スクリーニング(25~60歳)
    • その他の年齢層(1~25歳および60歳超)

第7章 鎌状赤血球貧血症の迅速POC検査市場:機関タイプの推定・動向分析

  • 機関タイプの市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:機関タイプ別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • 政府ラボ
    • プライベートラボ
    • コーポレートラボ
    • PPP(官民パートナーシップ)

第8章 鎌状赤血球貧血症の迅速POC検査市場:最終用途の推定・動向分析

  • 最終用途の市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:最終用途別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • 研究機関
    • 病院・診療所
    • 診断検査室
    • 在宅ケア環境
    • その他

第9章 鎌状赤血球貧血症の迅速POC検査市場:流通チャネルの推定・動向分析

  • 流通チャネルの市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 世界の鎌状赤血球貧血症の迅速POC検査市場:流通チャネル別展望
  • 市場規模と予測・動向分析(2018年~2030年)
    • B2B(企業間取引)
    • B2C(企業対消費者)

第10章 鎌状赤血球貧血症の迅速POC検査市場:地域の推定・動向分析

  • 地域の市場シェア分析、2024年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測・動向分析(2018年~2030年)
  • 北米
    • 北米:SWOT分析
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 欧州:SWOT分析
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • アジア太平洋:SWOT分析
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ラテンアメリカ:SWOT分析
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 中東・アフリカ:SWOT分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第11章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析(2024年)
    • BIOMEDOMICS INC.
    • Silver Lake Research Corporation
    • Bio-Rad Laboratories, Inc.
    • Trivitron Healthcare
    • Hemex Health
    • Sysmex Corporation
    • EKF Diagnostics Holdings plc.
    • HemoCue America(Danaher)
    • Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 List of Secondary Sources
  • Table 3 Regulatory Framework
  • Table 4 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 6 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 7 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 USD Million
  • Table 8 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 9 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 10 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 12 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 13 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 14 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 15 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 16 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 17 North America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 19 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 20 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 21 U.S Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 22 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 23 U.S. Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 25 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 26 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 27 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 28 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 29 Canada Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 31 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 32 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 33 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 34 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35 Mexico Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 37 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 38 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 39 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 40 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 41 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 42 Europe Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 44 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 45 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 46 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 47 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 48 UK Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 51 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 52 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 53 Germany America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 54 Germany Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 56 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 57 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 58 France Rapid Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 59 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 60 France Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 62 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 63 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 64 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 65 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 66 Spain Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 68 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 69 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 70 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 71 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 Italy Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 74 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 75 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 76 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 77 Asia Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 78 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 79 Asia-Pacific Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 80 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 81 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 82 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 83 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 84 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 China Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 86 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 87 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 88 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 89 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 90 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91 Japan Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 92 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 93 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 94 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 95 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 96 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 97 India Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 98 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 99 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 100 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 101 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 102 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 103 South Korea Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 104 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 105 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 106 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 107 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 108 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 109 Australia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 110 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 111 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 112 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 113 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 114 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 115 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 116 Latin America Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 117 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 118 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 119 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 120 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 121 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 122 Brazil Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 123 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 124 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 125 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 126 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 127 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 128 Argentina Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 129 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Country, 2018 - 2030 (USD Million)
  • Table 130 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 131 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 132 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 133 Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 134 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 135 MEA Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 136 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 137 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 138 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 139 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 140 South Africa Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 141 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 142 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 143 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 144 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 145 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 146 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 147 UAE Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million) million
  • Table 148 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Type, 2018 - 2030 (USD Million)
  • Table 149 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Technology, 2018 - 2030 (USD Million)
  • Table 150 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Age Group, 2018 - 2030 (USD Million)
  • Table 151 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Sector Type, 2018 - 2030 (USD Million)
  • Table 152 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By End Use, 2018 - 2030 (USD Million)
  • Table 153 Saudi Arabia Rapid Point-of-Care Testing for Sickle Cell Anemia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Rapid Point-of-Care Testing for Sickle Cell Anemia: market outlook
  • Fig. 14 Rapid Point-of-Care Testing for Sickle Cell Anemia competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook.
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Rapid Point-of-Care Testing for Sickle Cell Anemia driver impact
  • Fig. 20 Rapid Point-of-Care Testing for Sickle Cell Anemia restraint impact
  • Fig. 21 Rapid Point-of-Care Testing for Sickle Cell Anemia strategic initiatives analysis
  • Fig. 22 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type movement analysis
  • Fig. 23 Rapid Point-of-Care Testing for Sickle Cell Anemia: Type outlook and key takeaways
  • Fig. 24 Lateral Flow Immunoassay market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Paper-Based Rapid Diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology movement analysis
  • Fig. 28 Rapid Point-of-Care Testing for Sickle Cell Anemia: Technology outlook and key takeaways
  • Fig. 29 Hemoglobin Electrophoresis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Isothermal Amplification Assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group movement analysis
  • Fig. 34 Rapid Point-of-Care Testing for Sickle Cell Anemia: Age Group outlook and key takeaways
  • Fig. 35 Newborn Screening (12 months and below) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Adult Screening (25 to 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Other Age Groups (1 to 25 & Above 60 years) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type movement analysis
  • Fig. 39 Rapid Point-of-Care Testing for Sickle Cell Anemia: Sector Type outlook and key takeaways
  • Fig. 40 Government Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Private Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Corporate Labs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 PPP (Public-Private-Partnerships) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use movement analysis
  • Fig. 45 Rapid Point-of-Care Testing for Sickle Cell Anemia: End use outlook and key takeaways
  • Fig. 46 Hospitals & Clinics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Diagnostics Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Research Institutions market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Homecare Settings market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution movement analysis
  • Fig. 52 Rapid Point-of-Care Testing for Sickle Cell Anemia: Distribution Channel outlook and key takeaways
  • Fig. 53 B2B (Business-to-Business) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 54 B2C (Business-to-Consumer) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Global rapid point-of-care testing for sickle cell anemia market: Regional movement analysis
  • Fig. 56 Global rapid point-of-care testing for sickle cell anemia market: Regional outlook and key takeaways
  • Fig. 57 Global rapid point-of-care testing for sickle cell anemia market shares and leading players
  • Fig. 58 North America
  • Fig. 59 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 60 U.S.
  • Fig. 61 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 62 Canada
  • Fig. 63 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 64 Mexico
  • Fig. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 66 Europe
  • Fig. 67 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 68 UK
  • Fig. 69 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 70 Germany
  • Fig. 71 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 72 France
  • Fig. 73 France market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Italy
  • Fig. 75 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 76 Spain
  • Fig. 77 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 78 Denmark
  • Fig. 79 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 80 Sweden
  • Fig. 81 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 82 Norway
  • Fig. 83 Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific
  • Fig. 85 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 86 China
  • Fig. 87 China market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Japan
  • Fig. 89 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 90 India
  • Fig. 91 India market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 92 Thailand
  • Fig. 93 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 South Korea
  • Fig. 95 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 96 Australia
  • Fig. 97 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 98 Latin America
  • Fig. 99 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 100 Brazil
  • Fig. 101 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 102 Argentina
  • Fig. 103 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 104 Middle East and Africa
  • Fig. 105 Middle East and Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 106 South Africa
  • Fig. 107 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 108 Saudi Arabia
  • Fig. 109 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 110 UAE
  • Fig. 111 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 112 Kuwait
  • Fig. 113 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 114 Market share of key market players- Rapid Point-of-Care Testing for Sickle Cell Anemia
目次
Product Code: GVR-4-68040-567-0

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Growth & Trends:

The global rapid point-of-care testing for sickle cell anemia market size is expected to reach USD 522.83 million by 2030, registering a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sickle Cell Disease (SCD) is a genetic blood disorder that results in the production of abnormally shaped red blood cells, leading to severe pain, anemia, and potential organ damage due to these sickle-shaped cells obstructing blood flow. India, according to the Journal of Hematology and Allied Science (JHAS), has one of the highest frequencies of the sickle B-globin allele. Early and accurate detection of SCD is critical for effective management and treatment. Traditional diagnostic methods often require specialized healthcare facilities and well-equipped laboratories, which may be inaccessible in resource-limited areas. This challenge has driven the growth of rapid point-of-care (POC) testing technologies, offering a more efficient and accessible alternative for diagnosing SCD.

POC testing offers several benefits, including fast results, ease of use, and suitability for decentralized healthcare settings. These features are particularly advantageous in regions with high SCD prevalence, where early diagnosis and intervention can substantially improve patient outcomes. By enabling timely detection, POC testing helps in better disease management, reducing the risk of severe complications and mortality associated with undiagnosed SCD. Furthermore, POC tests play a key role in newborn screening programs, helping to identify affected infants at birth and begin treatment immediately. Recent advancements in lateral flow immunoassays (LFIA) have significantly improved the diagnosis of SCD, particularly in low-resource settings. One innovative development is the multiplexed, allele-specific recombinase polymerase amplification (RPA) assay, which uses a lateral flow readout to detect multiple mutations in the B-globin gene, the primary cause of SCD, offering an efficient and accurate rapid diagnostic method. Additionally, integrating optical nanoparticles into LFIA platforms has enhanced the sensitivity and specificity of these tests, making them powerful diagnostic tools for SCD and other diseases.

Another notable innovation is the E-junction lateral flow immunoassay, designed for large-scale SCD screening in low- and middle-income countries (LMICs). This affordable, user-friendly POC device can diagnose healthy individuals, SCD patients, and carriers using just a single drop of whole blood. Its cost-effectiveness and reliability make it ideal for areas with limited access to traditional diagnostic methods, helping address the high mortality rates caused by delayed diagnoses. Similarly, the Sickle SCAN POC device demonstrates impressive sensitivity and specificity in detecting hemoglobin variants HbA, HbS, and HbC. It works effectively with both liquid blood and dried blood spots (DBS), even in samples containing high levels of fetal hemoglobin (HbF), making it an excellent choice for widespread screening in resource-constrained regions. The HemoTypeSC test, another promising tool for early SCD detection, is also highly sensitive and specific, particularly useful for large-scale screening programs. Mobile health units and community outreach programs, often led by NGOs, are also integral to providing rapid POC testing in resource-poor settings. These efforts not only enhance access to diagnostic services but also raise awareness about SCD and the importance of early intervention. Moreover, partnerships between NGOs and private companies have helped subsidize diagnostic tests, making them more affordable and scalable across various healthcare environments.

Targeted initiatives, such as the National Sickle Cell Anaemia Elimination Mission (NSCAEM), aim to eradicate sickle cell anemia as a public health issue by 2047 through universal screening, awareness campaigns, and improved disease management. The mission aims to screen about 70 million people aged 0-40, initially focusing on high-prevalence states like Gujarat and Maharashtra, while collaborating with the National Health Mission (NHM) for effective resource utilization.

Rapid Point-of-Care Testing for Sickle Cell Anemia Market Report Highlights:

  • Based on type, the lateral flow immunoassay segment led the market in 2024 with a 51.66% share, due to its affordability, ease of use, and fast, accurate results. LFIA's ability to detect multiple hemoglobin variants and its suitability for low-resource settings contribute to its increasing adoption in global diagnostics.
  • Based on technology, the hemoglobin electrophoresis segment led the market in 2024 with a 48.99% share, driven by its high accuracy in detecting hemoglobinopathies. As a reliable diagnostic method, it allows for precise identification of sickle cell disease and other hemoglobin variants, making it crucial for early intervention and disease management.
  • Based on age group, the newborn screening (12 months and below) segment led the market in 2024 and is expected to witness the fastest CAGR during the forecast period, due to growing awareness and the importance of early diagnosis. Early detection through POC testing allows for prompt treatment, reducing complications and improving long-term outcomes for affected infants.
  • The government laboratories sector type segment is experiencing significant growth, driven by national initiatives and technological advancements. The Indian Council of Medical Research (ICMR) has endorsed existing POC tests for sickle cell disease screening, encouraging states to implement one or two-level screening approaches.
  • The hospitals & clinics end use segment is experiencing substantial growth, driven by the increasing prevalence of sickle cell disease and the demand for timely diagnostics.
  • Based on distribution channel, the Business-to-Business (B2B) segment is experiencing significant growth, driven by increasing demand for accessible and efficient diagnostic solutions. Companies are forming strategic partnerships to expand their product offerings and reach broader markets.
  • North America dominated the global Rapid point-of-care testing for sickle cell anemia industry with a revenue share of 43.97% in 2024, driven by increasing demand for accessible and efficient diagnostic solutions. This expansion is attributed to factors such as the rising prevalence of chronic diseases, advancements in diagnostic technologies, and increased funding from government and private institutions.
  • Companies like BioMedomics and Silver Lake Research are leading the way with highly sensitive and specific tests, such as Sickle SCAN and HemoTypeSC, respectively, while others are leveraging global distribution networks to reach underserved populations. The market is poised for growth as these players work to enhance diagnostic capabilities, reduce turnaround times, and support early intervention efforts for sickle cell disease

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Technology
    • 1.2.3. Age group
    • 1.2.4. Sector Type
    • 1.2.5. End Use
    • 1.2.6. Distribution Channel
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type Outlook
    • 2.2.2. Technology Outlook
    • 2.2.3. Age Group Outlook
    • 2.2.4. Sector Type
    • 2.2.5. End Use Outlook
    • 2.2.6. Distribution Channel
    • 2.2.7. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for personalized medicine and genomic research
      • 3.2.1.2. Growing prevalence of sickle cell disease (SCD)
      • 3.2.1.3. Advancements in diagnostic technology
      • 3.2.1.4. Government and NGO initiatives for early point-of-care (POC) screening
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Limited accessibility to advanced technologies
  • 3.3. Rapid Point-of-Care Testing for Sickle Cell Anemia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Type Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Lateral Flow Immunoassay
      • 4.4.1.1. Lateral Flow Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Paper-Based Rapid Diagnostics
      • 4.4.2.1. Paper-Based Rapid Diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Others
      • 4.4.3.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Technology Estimates & Trend Analysis

  • 5.1. Technology Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Technology Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hemoglobin Electrophoresis
      • 5.4.1.1. Hemoglobin Electrophoresis market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Polymerase Chain Reaction (PCR)
      • 5.4.2.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Isothermal Amplification Assays
      • 5.4.3.1. Isothermal Amplification Assays market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Others
      • 5.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Newborn Screening (12 months and below)
      • 6.4.1.1. Newborn Screening (12 months and below) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Adult Screening (25 to 60 years)
      • 6.4.2.1. Adult Screening (25 to 60 years) market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Other Age Groups (1 to 25 & Above 60 years)
      • 6.4.3.1. Other Age Groups (1 to 25 & Above 60 years) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Sector Type Estimates & Trend Analysis

  • 7.1. Sector Type Market Share, 2024 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Sector Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Government Labs
      • 7.4.1.1. Government Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Private Labs
      • 7.4.2.1. Private Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Corporate Labs
      • 7.4.3.1. Corporate Labs market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. PPP (Public-Private-Partnerships)
      • 7.4.4.1. PPP (Public-Private-Partnerships) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: End Use Estimates & Trend Analysis

  • 8.1. End Use Market Share, 2024 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by End Use Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. Research Institutions
      • 8.4.1.1. Research Institutions market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Hospitals & Clinics
      • 8.4.2.1. Hospitals & Clinics market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. Diagnostic Laboratories
      • 8.4.3.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Homecare Settings
      • 8.4.4.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Others
      • 8.4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Market Share, 2024 & 2030
  • 9.2. Segment Dashboard
  • 9.3. Global Rapid Point-of-Care Testing for Sickle Cell Anemia Market by Distribution Channel Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. B2B (Business-to-Business)
      • 9.4.1.1. B2B (Business-to-Business) market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.2. B2C (Business-to-Consumer)
      • 9.4.2.1. B2C (Business-to-Consumer) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Rapid Point-of-Care Testing for Sickle Cell Anemia Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2024 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. North America: SWOT Analysis
    • 10.5.2. U.S.
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.3. Canada
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.5.4. Mexico
      • 10.5.4.1. Key country dynamics
      • 10.5.4.2. Regulatory framework
      • 10.5.4.3. Competitive scenario
      • 10.5.4.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.6. Europe
    • 10.6.1. Europe: SWOT Analysis
    • 10.6.2. UK
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.3. Germany
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.4. France
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.5. Italy
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.6. Spain
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.7. Norway
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.8. Sweden
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.6.9. Denmark
      • 10.6.9.1. Key country dynamics
      • 10.6.9.2. Regulatory framework
      • 10.6.9.3. Competitive scenario
      • 10.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.7. Asia Pacific
    • 10.7.1. Asia Pacific: SWOT Analysis
    • 10.7.2. Japan
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.3. China
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.4. India
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.5. Australia
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.6. South Korea
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.7.7. Thailand
      • 10.7.7.1. Key country dynamics
      • 10.7.7.2. Regulatory framework
      • 10.7.7.3. Competitive scenario
      • 10.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.8. Latin America
    • 10.8.1. Latin America: SWOT Analysis
    • 10.8.2. Brazil
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.8.3. Argentina
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 10.9. MEA
    • 10.9.1. MEA: SWOT Analysis
    • 10.9.2. South Africa
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.3. Saudi Arabia
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.4. UAE
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 10.9.5. Kuwait
      • 10.9.5.1. Key country dynamics
      • 10.9.5.2. Regulatory framework
      • 10.9.5.3. Competitive scenario
      • 10.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2024
    • 11.3.4. BIOMEDOMICS INC.
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Services benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Silver Lake Research Corporation
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Services benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Bio-Rad Laboratories, Inc.
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Services benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Trivitron Healthcare
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Services benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Hemex Health
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Services benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Sysmex Corporation
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Services benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. EKF Diagnostics Holdings plc.
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Services benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. HemoCue America (Danaher)
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Services benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Rapid Point-of-Care Testing for Sickle Cell Anemias Inc
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Services benchmarking
      • 11.3.12.4. Strategic initiatives